Crinetics Pharmaceuticals stock opened at $34.51 on Tuesday. The company has a 50-day simple moving average of $36.10 and a 200-day simple moving average of $47.77. The firm has a market ...

Stifel initiates coverage on CRNX, a clinical-stage pharmaceutical company focused on endocrine diseases and tumors.

Crinetics (CRNX) announced that the European Medicines Agency has validated the marketing authorization application for paltusotine, the first ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on KalVista Pharmaceuticals (KALV – Research ...

Fintel reports that on March 25, 2025, Stifel initiated coverage of Crinetics Pharmaceuticals (NasdaqGS:CRNX) with a Buy recommendation. Analyst Price Forecast Suggests 114.68% Upside As of March 19, ...

Crinetics Pharmaceuticals has a 1-year low of $31.84 and a 1-year high of $62.53. The company has a market capitalization of $3.20 billion, a P/E ratio of -9.23 and a beta of 0.58.

Crinetics Pharmaceuticals, Inc. SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2025, the Compensation Committee of ...

Given this risk, we thought we'd take a look at whether Crinetics Pharmaceuticals (NASDAQ:CRNX) shareholders should be worried about its cash burn. In this article, we define cash burn as its ...

As of March 19, 2025, the average one-year price target for Crinetics Pharmaceuticals is $77.16/share. The forecasts range from a low of $55.55 to a high of $105.00. The average price target ...

(MENAFN- GlobeNewsWire - Nasdaq) SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2025, the Compensation Committee of ...